← Back to Screener
Nexentis Technologies Inc. Common Stock (NXTS)
Price$5.11
Favorite Metrics
Price vs S&P 500 (26W)-86.61%
Price vs S&P 500 (4W)13.01%
Market Capitalization$3.73M
All Metrics
Book Value / Share (Quarterly)$6.51
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-21.85%
Cash Flow / Share (Quarterly)$-9.65
Price vs S&P 500 (YTD)-64.72%
Gross Margin (TTM)66.20%
Net Profit Margin (TTM)-1024.74%
EPS (TTM)$-63.66
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-63.66
Revenue Growth (5Y)3.13%
EPS (Annual)$-217.64
ROI (Annual)-109.35%
Gross Margin (Annual)21.43%
Net Profit Margin (5Y Avg)-1641.43%
Cash / Share (Quarterly)$10.28
Revenue Growth QoQ (YoY)-78.02%
ROA (Last FY)-95.02%
Revenue Growth TTM (YoY)18.94%
EBITD / Share (TTM)$-25.84
ROE (5Y Avg)-109.23%
Operating Margin (TTM)-1414.70%
Cash Flow / Share (Annual)$-9.65
P/B Ratio0.23x
P/B Ratio (Quarterly)0.40x
Net Income / Employee (Annual)$-741,900
EV / Revenue (TTM)-7.17x
Net Interest Coverage (TTM)-2.92x
ROA (TTM)-84.10%
EPS Incl Extra (Annual)$-217.64
Current Ratio (Annual)4.19x
Quick Ratio (Quarterly)3.52x
3-Month Avg Trading Volume0.10M
52-Week Price Return-94.51%
Revenue / Employee (TTM)$29,800
P/S Ratio (Annual)17.77x
Asset Turnover (Annual)0.04x
52-Week High$129.85
Operating Margin (5Y Avg)-1614.45%
EPS Excl Extra (Annual)$-217.64
26-Week Price Return-78.47%
Quick Ratio (Annual)3.52x
13-Week Price Return-19.78%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)4.19x
Enterprise Value$-1.49M
Revenue / Share Growth (5Y)57.78%
Asset Turnover (TTM)0.03x
Revenue / Employee (Annual)$30,000
Inventory Turnover (Annual)2.32x
Pretax Margin (Annual)-2546.19%
Cash / Share (Annual)$10.28
3-Month Return Std Dev147.80%
Gross Margin (5Y Avg)62.56%
Net Income / Employee (TTM)$-949,400
ROE (Last FY)-109.35%
Net Interest Coverage (Annual)-1.47x
EPS Basic Excl Extra (Annual)$-217.64
Receivables Turnover (TTM)2.67x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$-63.66
Receivables Turnover (Annual)1.68x
ROI (TTM)-102.36%
P/S Ratio (TTM)17.90x
Pretax Margin (5Y Avg)-1718.15%
Revenue / Share (Annual)$8.80
Price vs S&P 500 (52W)-125.05%
Year-to-Date Return-56.55%
5-Day Price Return12.31%
EPS Normalized (Annual)$-217.64
ROA (5Y Avg)-113.47%
Net Profit Margin (Annual)-2472.86%
Month-to-Date Return7.13%
EBITD / Share (Annual)$-166.39
Operating Margin (Annual)-2057.14%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-102.19%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-63.66
P/B Ratio (Annual)0.57x
Inventory Turnover (TTM)2.20x
Pretax Margin (TTM)-1101.95%
Book Value / Share (Annual)$13.79
Price vs S&P 500 (13W)-28.63%
Beta1.79x
Revenue / Share (TTM)$1.51
ROE (TTM)-113.68%
52-Week Low$3.38
Industry Peers — Agricultural Chemicals(9)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NXTSNexentis Technologies Inc. Common Stock | 17.90x | 18.94% | 66.20% | — | $5.11 |
| NTRNutrien Ltd. Common Shares | 1.22x | 3.52% | 31.05% | 42.06% | $68.33 |
| CFCF Industries Holding, Inc. | 2.49x | 19.34% | 38.45% | 43.50% | $115.02 |
| MOSThe Mosaic Company | 0.59x | 8.36% | 15.78% | -0.61% | $22.19 |
| SMGThe Scotts Miracle-Gro Company | 1.06x | -5.85% | 31.47% | -18.33% | $61.08 |
| UANCVR Partners, LP | 2.20x | 15.36% | 40.47% | — | $126.23 |
| CBUSCibus, Inc. Class A Common Stock | 30.21x | -14.62% | 100.00% | — | $1.44 |
| AVDAmerican Vanguard Corporation | 0.17x | -5.88% | 28.65% | — | $3.03 |
| SNESSenesTech, Inc. Common Stock | 4.13x | 19.60% | 62.49% | — | $1.73 |
| EVGNEVOGENE LTD. | 1.88x | -53.54% | 49.04% | — | $0.75 |
About
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.